315 related articles for article (PubMed ID: 15203189)
1. Effects of alpha-tocopherol on an animal model of tauopathies.
Nakashima H; Ishihara T; Yokota O; Terada S; Trojanowski JQ; Lee VM; Kuroda S
Free Radic Biol Med; 2004 Jul; 37(2):176-86. PubMed ID: 15203189
[TBL] [Abstract][Full Text] [Related]
2. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies.
Nakashima H; Ishihara T; Suguimoto P; Yokota O; Oshima E; Kugo A; Terada S; Hamamura T; Trojanowski JQ; Lee VM; Kuroda S
Acta Neuropathol; 2005 Dec; 110(6):547-56. PubMed ID: 16228182
[TBL] [Abstract][Full Text] [Related]
3. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
4. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice.
Ishihara T; Zhang B; Higuchi M; Yoshiyama Y; Trojanowski JQ; Lee VM
Am J Pathol; 2001 Feb; 158(2):555-62. PubMed ID: 11159192
[TBL] [Abstract][Full Text] [Related]
5. Argyrophilic grain disease and Alzheimer's disease are distinguished by their different distribution of tau protein isoforms.
Tolnay M; Sergeant N; Ghestem A; Chalbot S; De Vos RA; Jansen Steur EN; Probst A; Delacourte A
Acta Neuropathol; 2002 Oct; 104(4):425-34. PubMed ID: 12200631
[TBL] [Abstract][Full Text] [Related]
6. [Animal models of tauopathies].
Higuchi M
Rinsho Shinkeigaku; 2006 Nov; 46(11):928-30. PubMed ID: 17432223
[TBL] [Abstract][Full Text] [Related]
7. Initiation and synergistic fibrillization of tau and alpha-synuclein.
Giasson BI; Forman MS; Higuchi M; Golbe LI; Graves CL; Kotzbauer PT; Trojanowski JQ; Lee VM
Science; 2003 Apr; 300(5619):636-40. PubMed ID: 12714745
[TBL] [Abstract][Full Text] [Related]
8. Effects of Tau on the activity of triose phosphate isomerase (TPI) in brain cells.
Park SA; Park HW; Kim NH; Kim YH; Kwak MJ; Shin JS; Kim CW
Neurochem Int; 2010 Jul; 56(8):886-92. PubMed ID: 20359515
[TBL] [Abstract][Full Text] [Related]
9. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform.
Ishihara T; Hong M; Zhang B; Nakagawa Y; Lee MK; Trojanowski JQ; Lee VM
Neuron; 1999 Nov; 24(3):751-62. PubMed ID: 10595524
[TBL] [Abstract][Full Text] [Related]
10. Repression of tau hyperphosphorylation by chronic endurance exercise in aged transgenic mouse model of tauopathies.
Leem YH; Lim HJ; Shim SB; Cho JY; Kim BS; Han PL
J Neurosci Res; 2009 Aug; 87(11):2561-70. PubMed ID: 19360903
[TBL] [Abstract][Full Text] [Related]
11. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein.
Spittaels K; Van den Haute C; Van Dorpe J; Bruynseels K; Vandezande K; Laenen I; Geerts H; Mercken M; Sciot R; Van Lommel A; Loos R; Van Leuven F
Am J Pathol; 1999 Dec; 155(6):2153-65. PubMed ID: 10595944
[TBL] [Abstract][Full Text] [Related]
12. Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein.
Feuillette S; Miguel L; Frébourg T; Campion D; Lecourtois M
J Neurochem; 2010 May; 113(4):895-903. PubMed ID: 20193038
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation.
Pérez M; Ribe E; Rubio A; Lim F; Morán MA; Ramos PG; Ferrer I; Isla MT; Avila J
Neuroscience; 2005; 130(2):339-47. PubMed ID: 15664690
[TBL] [Abstract][Full Text] [Related]
14. Transgenic zebrafish as a novel animal model to study tauopathies and other neurodegenerative disorders in vivo.
Paquet D; Schmid B; Haass C
Neurodegener Dis; 2010; 7(1-3):99-102. PubMed ID: 20173336
[TBL] [Abstract][Full Text] [Related]
15. Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy.
Cente M; Filipcik P; Pevalova M; Novak M
Eur J Neurosci; 2006 Aug; 24(4):1085-90. PubMed ID: 16930434
[TBL] [Abstract][Full Text] [Related]
16. Expression of a truncated human tau protein induces aqueous-phase free radicals in a rat model of tauopathy: implications for targeted antioxidative therapy.
Cente M; Filipcik P; Mandakova S; Zilka N; Krajciova G; Novak M
J Alzheimers Dis; 2009; 17(4):913-20. PubMed ID: 19542619
[TBL] [Abstract][Full Text] [Related]
17. Conditionally inducible tau mice--designing a better mouse model of neurodegenerative diseases.
Janus C
Genes Brain Behav; 2008 Feb; 7 Suppl 1():12-27. PubMed ID: 18184367
[TBL] [Abstract][Full Text] [Related]
18. Anatamopathological spectrum of tauopathies.
Revesz T; Holton JL
Mov Disord; 2003 Sep; 18 Suppl 6():S13-20. PubMed ID: 14502651
[TBL] [Abstract][Full Text] [Related]
19. Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration.
Kulic L; Wollmer MA; Rhein V; Pagani L; Kuehnle K; Cattepoel S; Tracy J; Eckert A; Nitsch RM
Neurobiol Aging; 2011 Oct; 32(10):1827-38. PubMed ID: 19942317
[TBL] [Abstract][Full Text] [Related]
20. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau.
Williams DR
Intern Med J; 2006 Oct; 36(10):652-60. PubMed ID: 16958643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
